SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Jones, O.
Right arrow Articles by Ahmed, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, O.
Right arrow Articles by Ahmed, A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Bone Grafts
*Bone Marrow Transplantation
*Lupus
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

research-article

Long-term follow-up after non-myeloablative transplant of bone and marrow in BXSB mice

OY Jones

Department of Pediatrics, Walter Reed Army Medical Center, Georgia Avenue, NW, Washington DC, USA olcay.jones{at}gmail.com

A Lacson

Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Mackenzie Health Sciences Centre. Edmonton, Alberta, Canada

X Zeng

R&D, SABiosciences Corporation, Executive Way, Frederick, MD, USA

JM Jones

Immunology Consultant, Potomac, MD, USA

K Katti

George Washington University School of Medicine, Washington, DC, USA

RA Cahill

Cardinal Glennon Hospital, South Grand Avenue, St. Louis, MO, USA

AA Ahmed

Department of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Gillham Road, Kansas City, MO, USA

We present long-term outcomes of BXSB mice after non-myeloablative bone marrow transplants using major histocompatability complex (MHC)-matched cells. Groups differed in sources of donor lymphocytes or mesenchymal stromal cells (MSC). Unfractionated marrow cells from green fluorescent protein (GFP) transgenic (Tg) mice (BMT group) or from RAG1–/– B6 mice (RAG group) were injected intravenously (i.v.) into irradiated (550 cGy) hosts. As a source of mesenchymal cells, bone chips from GFP-Tg were injected intraperitoneally alone (MSC group) or along with i.v. bone marrow cells (BMT + MSC group). Controls were untreated mice (UnTx) or mice exposed to radiation only (Rad Cont). At 62 weeks post-transplant, surviving mice were harvested for histopathology, flow cytometry and real time polymerase chain reaction (RT-PCR). The mice from BMT + MSC group had the best outcomes for survival rates (71.4% vs. 43.8%), renal scores (2.9% vs. 28.8% glomerular sclerosis) and percent splenic monocytes (4.2 vs. 11.3%) compared with mice from Rad Cont. Improvement in RAG and BMT groups was less prominent but were comparable with one another. Although MSC alone were not sufficient to control the renal pathology, it limited the expansion of CD4CD8 T cell populations without a change in Foxp3 expression. The results suggest the importance of the innate immune system in disease pathogenesis and a role for MSC in immunomodulation.

Key Words: mesenchymal stromal cells • rodent • stem cell • systemic lupus erythematosus • transplantation

Lupus, Vol. 18, No. 9, 813-821 (2009)
DOI: 10.1177/0961203309104391


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement